ELZONRIS is the first and only approved treatment for BPDCN, a deadly hematologic cancer.2,3
Efficacy in treatment-naive patients (n=29)1,4*
CR/CRc rate†
- Secondary endpoint in majority of treatment-naive cohorts‡
ORR
- Secondary endpoint
of patients bridged to SCT
- Secondary endpoint
- The median duration of CR/CRc was not reached at the time of analysis; median follow-up was 19 months (range, 1-42 months)1
- The median time to CR/CRc was 43 days (range, 14-131 days)1
- The median time from the first dose to SCT was 113 days (range, 72-203 days; n=21)4
Efficacy in the pivotal cohort (n=13)2,4
CR/CRc rate†
- Primary endpoint
ORR
- Secondary endpoint
of patients bridged to SCT
- Secondary endpoint
- The median duration of CR/CRc was not reached at the time of analysis (range, 3.9-12.2 months)2
- The median time to CR/CRc was 57 days (range, 14-107 days)2
Efficacy in other cohorts (n=16)4
- Efficacy measures included 88% CR/CRc rate,† 100% ORR, and 44% bridged to stem cell transplantation (all secondary endpoints)4
- The median duration of CR/CRc was not reached at the time of analysis (range, 1.3-57.4 months)4
*All-cohorts population includes patients from the pivotal cohort.1
†CRc defined as complete response with residual skin abnormality not indicative of active disease.2
‡CRc rate was the primary endpoint in Stage 3 and a secondary endpoint in Stages 1 and 2 of treatment-naive patients.4
BPDCN, blastic plasmacytoid dendritic cell neoplasm; CR, complete response; CRc, clinical complete response; ORR, overall response rate; SCT, stem cell transplantation.
- References:
- Pemmaraju N, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628-1637.
- ELZONRIS [prescribing information]. New York, NY: Stemline Therapeutics, Inc.; July 2023.
- Pagano L, et al. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202.
- Data on file. Stemline Therapeutics, Inc.